The Power of Combinative Capabilities: Facilitating the Outcome of Frequent Innovation in Pharmaceutical R&D Projects

被引：20
|
作者：
Biedenbach, Thomas [1 ]
机构：
[1] Umea Univ, Umea Sch Business, Umea, Sweden
来源：
PROJECT MANAGEMENT JOURNAL | 2011年 / 42卷 / 02期
关键词：
combinative capabilities; dynamic capabilities; project capabilities; multiproject capabilities; pharmaceutical innovation; DYNAMIC CAPABILITIES; ABSORPTIVE-CAPACITY; FRONT-END; KNOWLEDGE; ORGANIZATION; MANAGEMENT; PORTFOLIO; FIRM; FORM;
D O I：
10.1002/pmj.20221
中图分类号：
C93 [管理学];
学科分类号：
12 ; 1201 ; 1202 ; 120202 ;
摘要：
The purpose of this article is to investigate how organizations organize the early phases of research and development (R&D) projects in the pharmaceutical industry to achieve frequent innovation. The investigation was designed as a qualitative multiple case study. The analysis identified a standardized projectification of the preproject phases, leading to certain conflicts, such as a severe tension between dynamic, project, and multiproject capabilities, which hamper frequent innovation. Optimizing combinative capabilities to balance the capabilities triumvirate can provide powerful leverage and boost frequent innovation.
引用
收藏
页码：63 / 80
页数：18
相关论文
共 50 条
  • [1] Innovation capabilities for global R&D projects in subsidiaries
    Tarraco, Elisangela Lazarou
    Bernardes, Roberto Carlos
    Borini, Felipe Mendes
    Rossetto, Dennys Eduardo
    [J]. EUROPEAN JOURNAL OF INNOVATION MANAGEMENT, 2019, 22 (04) : 639 - 659
  • [2] Investment decisions in pharmaceutical R&D projects
    Pandey, M
    [J]. DRUG DISCOVERY TODAY, 2003, 8 (21) : 968 - 971
  • [3] Competencies of Bridge Managers for Facilitating Global R&D Projects
    Chalarak, Nawarerk
    Uchihira, Naoshi
    Sato, Nao
    [J]. INTERNATIONAL JOURNAL OF INNOVATION AND TECHNOLOGY MANAGEMENT, 2023, 20 (02)
  • [4] A decade of innovation in pharmaceutical R&D: the Chorus model
    Paul K. Owens
    Eyas Raddad
    Jeffrey W. Miller
    John R. Stille
    Kenneth G. Olovich
    Neil V. Smith
    Rosie S. Jones
    Joel C. Scherer
    [J]. Nature Reviews Drug Discovery, 2015, 14 : 17 - 28
  • [5] Innovation in pharmaceutical R&D: mapping the research landscape
    Angelo Kenneth S. Romasanta
    Peter van der Sijde
    Jacqueline van Muijlwijk-Koezen
    [J]. Scientometrics, 2020, 125 : 1801 - 1832
  • [6] A decade of innovation in pharmaceutical R&D: the Chorus model
    Owens, Paul K.
    Raddad, Eyas
    Miller, Jeffrey W.
    Stille, John R.
    Olovich, Kenneth G.
    Smith, Neil V.
    Jones, Rosie S.
    Scherer, Joel C.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (01) : 17 - 28
  • [7] R&D in the pharmaceutical industry and the US investment in innovation
    Wollowitz, S
    Kermani, F
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U251 - U251
  • [8] Innovation in pharmaceutical R&D: mapping the research landscape
    Romasanta, Angelo Kenneth S.
    van der Sijde, Peter
    Van Muijlwijk-Koezen, Jacqueline
    [J]. SCIENTOMETRICS, 2020, 125 (03) : 1801 - 1832
  • [9] Why is it hard to terminate failing projects in pharmaceutical R&D?
    Richard W. Peck
    Dennis W. Lendrem
    Iain Grant
    B. Clare Lendrem
    John D. Isaacs
    [J]. Nature Reviews Drug Discovery, 2015, 14 : 663 - 664
  • [10] Why is it hard to terminate failing projects in pharmaceutical R&D?
    Peck, Richard W.
    Lendrem, Dennis W.
    Grant, Iain
    Lendrem, B. Clare
    Isaacs, John D.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (10) : 663 - 664
12345